The Quantellect read.As of Nov 19, 2026, 10 active firms cover MoonLake Immunotherapeutics: 8 rate it Buy or better, 1 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. The target range is very wide, $10.00 to $70.00 (about 7.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $33.10 sits 207% above the current $10.78. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.94 next quarter toward $-3.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy880%
Neutral110%
Sell110%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$33.10
+207.1% upside
Average target across 10 active firms as of Nov 19, 2026 vs $10.78 current
Highest Target$70.00
Average Target$33.10
Lowest Target$10.00
Detailed analyst forecasts for MLTX
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 8 of 10 active firms rate MLTX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MLTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.94
Range $-1.18 – $-0.79 · 3 analysts · -4% YoY
Next period, 3 analysts expect MoonLake Immunotherapeutics to earn $-0.94 a share (range $-1.18 – $-0.79), versus $-0.98 a year earlier. Full-year consensus is $-3.58, growing to $-3.40 the year after.
REVENUE · NEXT QUARTER
$74.8K
Range $0 – $598.0K · 3 analysts
Revenue is expected to reach $74.8K (range $0 – $598.0K). Full-year consensus is $0, rising to $18.9M next year.
Top analysts covering MoonLake Immunotherapeutics
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MLTX.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$20.00+85.5% to target
Overall win rate
50%
+ Follow
#2
Serge Belanger
Needham · Rank #129
Buy
$30.00+178.3% to target
Overall win rate
46%
+ Follow
#3
Julian Harrison
BTIG · Rank #183
Buy
$30.00+178.3% to target
Overall win rate
41%
+ Follow
#4
SS
Samantha Semenkow
Citigroup · Rank #333
Sell
$6.00-44.3% to target
Overall win rate
41%
+ Follow
#5
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$35.00+224.7% to target
Overall win rate
41%
+ Follow
MLTX stock forecast FAQ
What is MLTX's average 12-month price target?+
The 10 active firms with a live target average $33.10 for MoonLake Immunotherapeutics over the next 12 months, ranging from a $70.00 high to a $10.00 low, as of Nov 19, 2026.
Is MLTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MLTX?+
The Street-high target is $70.00 (Clear Street), and the Street-low is $10.00 (Goldman Sachs). The average of all 10 active-firm targets is $33.10.
How many active Wall Street firms cover MLTX?+
10 active firms have a recognized rating on MoonLake Immunotherapeutics as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MLTX?+
Among analysts who currently cover MLTX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $20.00 target.
What is MoonLake Immunotherapeutics's projected EPS for next quarter?+
The consensus estimate is $-0.94 per share (range $-1.18 – $-0.79) across 3 analysts. Full-year EPS is projected at $-3.58, rising to $-3.40 the following year.
How much revenue is MoonLake Immunotherapeutics expected to report next quarter?+
Consensus revenue is $74.8K (range $0 – $598.0K). Full-year revenue is projected at $0, growing to $18.9M next year.
Have analysts been upgrading or downgrading MLTX lately?+
As of Nov 19, 2026, 8 of 10 active firms rate MLTX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MLTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.